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a b s t r a c t
Valerenic acid (VA) is a β2/3 subunit-speciﬁc modulator of γ-aminobutyric acid (GABA) type A (GABAA)
receptors inducing anxiolysis. Here we analyze if VA-esters can serve as prodrugs and if different ester
structures have different in vitro/in vivo effects. Modulation of GABAA receptors expressed in Xenopus
oocytes was studied with 2-microelectrode-voltage-clamp. Anxiolytic effects of the VA-esters were
studied on male C57BL/6N mice by means of the elevated plus maze-test; anticonvulsant properties
were deduced from changes in seizure threshold upon pentylenetetrazole infusion. VA was detected in
plasma conﬁrming hydrolysis of the esters and release of VA in vivo. Esteriﬁcation signiﬁcantly reduced
the positive allosteric modulation of GABAA (α1β3γ2S) receptors in vitro. in vivo, the studied VA-ester
derivatives induced similar or even stronger anxiolytic and anticonvulsant action than VA. While
methylation and propylation of VA resulted in faster onset of anxiolysis, the action of VA-ethylester was
longer lasting, but occurred with a signiﬁcant delay. The later ﬁnding is in line with the longer lasting
anticonvulsant effects of this compound. The estimated VA plasma concentrations provided ﬁrst insight
into the release kinetics from different VA-esters. This might be an important step for its future clinical
application as a potential non-sedative anxiolytic and anticonvulsant.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
γ-Aminobutyric acid (GABA) type A receptors (GABAA) are the
major inhibitory neurotransmitter receptors in the mammalian
brain. GABAA receptors belong to the superfamily of Cys-loop-type
ligand-gated ion channels (Olsen and Sieghart, 2008). Nineteen
GABAA receptor subunits have been identiﬁed in the human
genome, comprising α1–6, β1–3, γ1–3, δ, ε, θ, π and ρ1–3 (Simon
et al., 2004). Five receptor subunits form a chloride-selective ion
channel. Receptor activation opens the channel and induces
transmembrane chloride currents (IGABA) modulating neuronal
excitability and transmitter release (Sieghart, 2006; Sigel and
Steinmann, 2012). There is consensus that the major adult receptor
isoform consists of 2α1, 2β2 and one γ2 subunit (Olsen and
Sieghart, 2008).
GABAA receptors play a major role in the treatment of central
nervous system (CNS) diseases such as generalized anxiety and
panic disorders, epilepsy, and sleep disturbances (Möhler, 2006).
They are the molecular target of the classical benzodiazepines (e.g.
diazepam) and subtype-selective benzodiazepine site ligands such
as zolpidem or zopiclone, barbiturates, anaesthetics, and antic-
onvulsants (Sigel and Steinmann, 2012). Beside these drugs,
GABAA receptors are modulated by multiple natural products
(Johnston et al., 2006).
We and others have shown that valerenic acid (VA), a consti-
tuent of Valeriana ofﬁcinalis, enhances IGABA through GABAA
receptors. VA binds with nanomolar afﬁnity (Benke et al., 2009)
and modulates GABAA receptors in an allosteric manner. VA
selectively interacts with receptors comprising β2/3-subunits
(Benke et al., 2009; Khom et al., 2007). A point mutation in the
β2-subunit (N265S) of recombinant receptors prevents IGABA
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enhancement while the “reversed mutation” in β1 (S266N)
enhances current stimulation to extents observed on β2/3-subunit
containing receptors (Khom et al., 2007). Valerenic acid induces
anxiolysis in the elevated plus maze and the light/dark choice test
in mice (Benke et al., 2009; Khom et al., 2010). Anxiolysis was
absent in β3(N265M) point-mutated mice supporting the hypoth-
esis that the anxiolytic effects of VA are caused by interaction with
β3-containing GABAA receptors (Benke et al., 2009).
A recently published pharmacokinetic study on rats revealed
that approximately 34% of VA are absorbed after oral administra-
tion with a half-life between 2.7 and 5 h (Sampath et al., 2012).
This good bioavailability is in line with the reported anxiolysis of
VA after oral administration in mice (Benke et al., 2009).
Together these ﬁndings make VA or one of its derivatives
(Khom et al., 2010; Kopp et al., 2010) interesting drug candidates.
Little is known, however, how this molecule penetrates the blood-
brain barrier (Neuhaus et al., 2008). Ester prodrugs can en-
hance the lipophilicity (by masking charged groups such as
carboxylic acids) and thereby affect the time course of drug action
(Beaumont et al., 2003). Therefore four VA-esters (VA-methylester
(VA-ME), VA-ethylester (VA-EE), VA-propylester (VA-PE) and VA-
pivaloyloxymethylester (VA-POM)) have been synthesized in order
to address the following questions about the biological activity of
these potential prodrugs: (i) Does esteriﬁcation affect modulation
of IGABA through GABAA receptors? (ii) Do VA-esters represent
prodrugs (i.e. are esters hydrolyzed in vivo and is VA detectable in
the plasma? (iii) Are VA-esters active in vivo and – if so – does
esteriﬁcation affect the anxiolytic and anticonvulsant properties
of VA?
2. Materials and methods
All experiments on animals were carried out in accordance to
the Austrian Animal Experimental Law, which is in line with the
EU directive 2010/63/EU.
2.1. Chemicals
Valerenic acid (VA) was purchased from HWI Pharma Solutions
(Rülzheim, Germany) and converted into the aforementioned
derivatives as described below (for structural formulae see
Fig. 1). Chemicals used in this study were obtained from Sigma-
Aldrich (Vienna, Austria) except where otherwise stated. Dichlor-
omethane (DCM), dimethylsulfoxide (DMSO), formic acid, metha-
nol and t-butylmethylether were of p.a. quality and purchased
from ROTH (Karlsruhe, Germany). For HPLC analysis double dis-
tilled water and acetonitrile, HPLC quality (VWR Int., Vienna,
Austria) were used.
LogP values for the aimed compounds were calculated using
ACD/ChemSketch freeware.
All reactions were carried out in oven dried 4 ml-reaction vials
under an argon atmosphere. DCM was predistilled and then
desiccated on Al2O3 columns (PURESOLV, Innovative Technology;
Amesbury, USA). Reaction mixtures were magnetically stirred and
monitored by thin layer chromatography using Merck Silica 60F254
plates (Merck, Vienna, Austria). Flash chromatography was per-
formed on a Sepacore Flash System (2 Büchi Pump Module
C-605, Büchi Pump Manager C-615, Büchi UV Photometer C-635,
Büchi Fraction Collector C-660; Büchi Labortechnik, Flawil, Swit-
zerland) using Merck silica gel (0.040–0.063 mm, 230–400 mesh).
Yields refer to chromatographically and spectroscopically pure
compounds. 1H-NMR (200 MHz) and 13C-NMR (50 MHz) were
recorded on Bruker AC 200 (200 MHz; Bruker, Karlsruhe, Ger-
many). The chemical shifts δ are reported relative to the residual
solvent peaks. All 1H and 13C shifts are given in ppm (s¼singulet,
d¼doublet, t¼triplet, q¼quadruplet, m¼multiplet). Speciﬁc rota-
tion was measured on an Anton Paar MCP500 polarimeter (Anton
Paar GmbH; Graz, Austria) at 20 1C in DCM.
LC–MS/MS analyses were carried out on an Ultimate 3000
RSLC-series system (Thermo Fisher Scientiﬁc Austria, Vienna,
Austria) coupled to a triple quadrupol mass spectrometer API
4000 (AB Sciex Instruments, Framingham, USA).
2.2. Synthesis of valerenic acid esters
2.2.1. Valerenic acid methylester (VA-ME)
Valerenic acid (30.0 mg, 1 Eq., 0.13 mmol) and 4-dime
thylaminopyridine (DMAP, 1.6 mg, 0.1 Eq, 0.01 mmol) were dis-
solved in 1.3 ml dry DCM under an Argon atmosphere and cooled
to 0 1C, then 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
(EDCI; 36.8 mg, 1.5 Eq, 0.19 mmol) was added in one portion. After
stirring the mixture for ﬁve min methanol (23.7 μl, 4.5 Eq,
0.59 mmol) was added dropwise and the mixture was left warm-
ing to room temperature overnight. The solution was taken up in
50 ml ethylacetate (EtOAc) and was subsequently washed with
saturated NH4Cl solution (three times), saturated NaHCO3 solution
(three times) and once with brine; it was then dried and
concentrated under reduced pressure. Puriﬁcation of the crude
material via column chromatography (LP:EtOAc¼30:1) provided
30.2 mg (94%) of Valerenic acid methylester as a colorless oil.
 1H-NMR (200 MHz, CDCl3): δ¼0.77 (d, J1¼7.0, 3H), 1.37–1.98
(m, 14H), 2.19 (t, J1¼7.5 Hz, 1H), 2.90–2.99 (m, 1H), 3.49–3.56
(m, 1H), 3.72 (s, 3H), 7.01 (dq, J1¼1.4 Hz, J2¼9.8 Hz, 1H) 13C-NMR (50 MHz, CDCl3) δ¼12.0 (s), 12.4 (s), 13.5 (s), 24.5 (d),
25.4 (d), 28.7(d), 33.0 (t), 34.3 (t), 37.4 (d), 47.4 (t), 51.7 (s), 125.7
(q), 130.9 (q), 133.4 (t), 169.0 (q)
Analytical data is consistent with the reported data for Valere-
nic acid methylester (Kopp et al., 2010).
2.2.2. Valerenic acid ethylester (VA-EE)
Using the analogous procedure as for the preparation of
VA-ME, treatment of valerenic acid (20.0 mg, 1 Eq, 0.09 mmol)
with 4-dimethylaminopyridine (1.0 mg, 0.1 Eq, 0.009 mmol), EDCI
(24.4 mg, 1.5 Eq, 0.13 mmol) and ethanol (22.3 μl, 4.5 Eq,
0.38 mmol) yielded 20.2 mg (95%) of VA-EE as colorless oil.
 1H-NMR (200 MHz, CDCl3, ppm): δ¼0.78 (d, J¼7.0, 3H), 1.29 (t,
J¼7.1 Hz, 3H), 1.37–2.02 (m, 14H), 2.19 (t, J¼7.6 Hz, 2H), 2.92–
2.98 (m, 1H), 3.46–3.56 (m, 1H), 4.17 (q, J¼7.1 Hz, 2H), 7.01 (dq,
J1¼9.8 Hz, J2¼1.4 Hz, 1H) 13C-NMR (50 MHz, CDCl3, ppm): δ¼12.0 (s), 12.4 (s), 13.5 (s),
14.3 (s), 24.5 (d), 25.5 (d), 28.7(d), 33.1 (t), 34.3 (t), 37.4 (d), 47.4
(t), 60.4 (d), 125.7 (q), 130.9 (q), 133.4 (t), 169.0 (q)
Analytical data is consistent with the reported data for Valere-
nic acid ethylester (Kopp et al., 2010).
2.2.3. Valerenic acid propylester (VA-PE)
Using the analogous procedure as for the preparation of VA-ME,
treatment of valerenic acid (30.0 mg, 1 Eq, 0.13 mmol) with 4-DMAP
(1.6 mg, 0.1 Eq, 0.01 mmol), EDCI (36.8 mg, 1.5 Eq, 0.19 mmol) and
propanol (28.5 μl, 4.5 Eq, 0.38 mmol) yielded 35.1 mg (99%) of
VA-PE as colorless oil.
 1H-NMR (200 MHz, CDCl3, ppm): δ¼0.77 (d, J¼7.0, 3H), 0.95
(t, J¼7.4 Hz, 3H), 1.37–2.01 (m, 16H), 2.19 (t, J¼7.7 Hz, 2H),
2.91–2.97 (m, 1H), 3.48–3.55 (m, 1H), 4.07 (t, J¼6.7 Hz, 2H),
7.02 (dq, J1¼9.8 Hz, J2¼1.3 Hz, 1H)
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 13C-NMR (50 MHz, CDCl3, ppm) δ¼10.5 (s), 12.0 (s), 12.4 (s),
13.5 (s), 24.5 (d), 25.5 (d), 28.7(d), 33.1 (t), 34.3 (t), 37.4 (d), 47.4
(t), 66.0 (d), 126.0 (q), 130.7 (q), 133.5 (q), 143.3 (d) 168.7 (q)
[α]20D ¼77.0 (c¼0.2, DCM);
2.2.4. Valerenic acid pivaloyloxymethylester (VA-POM)
Valerenic acid (20 mg, 1 Eq, 0.13 mmol) and 1,8-diazabicycloun-
dec-7-ene (21.4 μL, 1.1 Eq, 0.14 mmol) were dissolved in dry DCM
(1.3 ml) under an argon atmosphere; pivaloyloxymethyl chloride
(20.2 μl, 1.1 Eq, 0.14 mmol) was added dropwise (Urban et al.,
2005). The mixture was stirred overnight until full conversion
before it was taken up in 50 ml EtOAc and subsequently washed
three times with saturated NH4Cl and NaHCO3 solution and one
time with brine. The organic phase was dried and concentrated in
vacuo. Puriﬁcation by column chromatography (LP:EtOAc¼4:1)
furnished 19.1 mg (85%) of VA-POM as a slightly yellow oil.
 1H-NMR (200 MHz, CDCl3, ppm): δ¼0.78 (d, J¼6.9, 3H), 1.21 (s,
9H), 1.38–1.98 (m, 15H), 2.20 (t, J¼7.4 Hz, 2H), 2.91–2.95 (m,
1H), 3.50–3.55 (m, 1H), 5.81 (s, 2H), 7.09 (dq, J1¼9.8 Hz,
J2¼1.1 Hz, 1H) 13C-NMR (50 MHz, CDCl3, ppm) δ¼12.0 (s), 12.2 (s), 13.5 (s),
24.5 (d), 25.3 (d), 26.8 (s), 28.7(d), 33.0 (t), 34.3 (t), 37.4 (d), 38.8
(q), 47.4 (t), 79.9 (d), 125.0 (q), 131.2 (q), 133.1 (q), 145.6
(d) 167.0 (q), 177.2(q)
[α]20D ¼70.4 (c¼0.6, DCM);
2.3. Expression and functional characterization of GABAA receptors
Preparation of stage V–VI oocytes from Xenopus laevis (Nasco, Ft.
Atkinson, WI), synthesis of capped off run-off poly(Aþ) cRNA
transcripts from linearized cDNA templates (pCMV vector) was
performed as described (Khom et al., 2006). Brieﬂy, female Xenopus
laevis were anaesthetized by exposing them for 15 min to a 0.2%
solution of MS-222 (methane sulfonate salt of 3-aminobenzoic acid
ethyl ester), before surgically removing parts of the ovaries. Follicle
membranes from isolated oocytes were enzymatically digested
with 2 mg/ml collagenase (Type 1 A). One day after isolation, the
oocytes were injected with about 10–50 nl of diethylpyrocarbonate
—treated water containing the different cRNAs at a concentration of
approximately 150–3000 ng/μl/subunit. The amount of cRNA was
determined by means of a NanoDrop ND-1000 (Kisker-biotech,
Steinfurt, Germany). To ensure expression of the γ-subunit in the
case of α1β3γ2S receptors, cRNAs were mixed in a ratio of 1:1:10
(Boileau et al., 2002). Oocytes were stored at 18 1C in ND96 solution
(Methfessel et al., 1986). Electrophysiological experiments were
conducted using the two-microelectrode voltage-clamp method at
a holding potential of 70 mV using a TURBO TEC 01C ampliﬁer
(npi electronic, Tamm, Germany) and an Axon Digidata 1322 A
interface (Molecular Devices, Sunnyvale, CA) applying pCLAMP v.
9.2 data acquisition. The bath solution consisted of 90 mM NaCl,
1 mM KCl, 1 mM MgCl2 6H2O, 1 mM CaCl2 and 5 mM 2-(4-(2-
hydroxyethyl)-1-piperazinyl)-ethanesulfonic acid (HEPES; pH 7.4).
Microelectrodes were ﬁlled with 2 M KCl and had resistances
between 1 and 3 MΩ (Khom et al., 2006).
2.4. Perfusion system
GABA and the tested compounds were applied by means of
fast perfusion system (Baburin et al., 2006). Drug or control
solutions were applied by means of a TECAN Miniprep 60 (npi
electronic, Tamm, Germany) permitting automation of the experi-
ments. To elicit IGABA the chamber was perfused with 120 ml of
GABA-containing solution at volume rate between 300 and
1000 ml/s. The IGABA rise time ranged between 100 and 250 ms.
To account for possible slow recovery from increasing levels of
desensitization in the presence of high compound concentrations,
the duration of washout periods was extended from 1.5 min (GABA
EC3–7) to 3 min (co-application of GABA EC3–7 and 1 mM com-
pound) to 5–10 min (co-application of GABA EC3–7 and 10 mM
compound) to 15–20 min (co-application of GABA EC3–7 and
Fig. 1. Structural formulae of VA and synthesized ester derivatives.
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30 mM compound) to 30 min (GABA EC3–7 and 100 mM compound).
Oocytes with maximal current amplitudes 43 mA were discarded
to exclude voltage-clamp errors (Khom et al., 2006).
2.5. Analyzing concentration–response curves
Stimulation of chloride currents by modulators of the GABAA
receptor was measured at a GABA concentration eliciting between
3 and 7% of the maximal current amplitude (EC3–7). The EC3–7 was
determined at the beginning of each experiment.
Enhancement of the chloride current was deﬁned as
(I(GABAþCompound)/IGABA)1, where I(GABAþCompound) is the current
response in the presence of the compound and IGABA is the control
GABA current. Each data point represents the mean7S.E.M from
at least 5 oocytes and Z2 oocyte batches.
2.6. Behavioral analysis
2.6.1. Animals
Male mice (C57BL/6N) were obtained from Charles River
Laboratories (Sulzfeld, Germany). For maintenance, mice were
group-housed (maximum 5 mice per type IIL cage) with free
access to food and water. At least 24 h before the commencement
of experiments, mice were transferred to the testing facility, where
they were given free access to food and water. The temperature in
the maintenance and testing facilities was 2272 1C; the humidity
was 40–60%; a 12 h light-dark cycle was in operation (lights on
from 07.00 to 19.00). Only male mice – aged 3–6 months – were
tested. Compounds at a dose of 3 mg/kg bodyweight or solvent
alone were applied by intraperitoneal (i.p.) injection. The dose was
chosen according to a previously published dose–response curve
(Khom et al., 2010). Testing solutions were prepared in a solvent
composed of saline (0.9% NaCl solution with 10% DMSO and 3%
Polysorbat 80). The ﬁnal DMSO concentration was ﬁxed to 10%
(Broadwell et al., 1982). Application of the solvent alone did not
inﬂuence animal behavior.
2.6.2. Elevated plus maze (EPM) test
The animals’ behavior was tested over 5 min on an elevated
plus maze 1 m above ground consisting of two closed and two
open arms, each 505 cm in size. The test instrument was built
from grey PVC; the height of closed arm walls was 20 cm.
Illumination intensity was set to 180 lx. Animals were placed in
the center, facing an open arm. Analysis of open and closed arm
entries, distance and time on open arm was automatically done
with Video-Mot 2 equipment and software (TSE systems, Bad
Homburg, Germany). Drugs or solvent were applied 15, 30 or
60 min before testing.
2.6.3. Seizure threshold
Seizure threshold was determined by pentylenetetrazole (PTZ)
tail-vein infusion on freely moving animals at a rate of 100 ml/min
(10 mg/ml PTZ in saline). Infusion was stopped when animals
displayed generalized clonic seizures. Animals were killed by
cervical displacement immediately after the ﬁrst generalized
seizure. The seizure threshold dose was calculated from the
infused volume in relation to body weight. The compounds were
injected 15, 30, 60, 90, 120 or 150 min before PTZ infusion. At the
infusion rate of 100 ml/min, generalized seizures are induced
within 90 s.
2.7. Detection of free VA in the plasma
2.7.1. Sampling
Blood samples were taken 15, 30, 60 and 120 min after i.p.
injection of the compounds. 10 min after i.p injection of thiopental
(150 mg/kg bodyweight in 0.9% sodium chloride solution) blood
samples (500–800 ml) were collected and compiled into ethylene-
diamine tetra-acetic acid (EDTA)-coated micro tubes (1.6 mg
EDTA/sample) and centrifuged at 12,000 rpm for 5 min at 4 1C.
Plasma samples were transferred into 1.5 ml tubes and stored at
80 1C until analysis.
2.7.2. Sample preparation
A liquid–liquid extraction method together with an internal
standard (IS) acetoxyvalerenic acid (ACVA; PhytoLab GmbH&Co
KG, Vestenbergsgreuth, Germany) was applied for the quantiﬁca-
tion of VA in plasma. To 100 ml of plasma sample 10 ml of IS
solution (1 mg/ml 10% aqueous DMSO) was added. These solutions
were extracted by liquid–liquid partition with 400 ml of dichlor-
omethane/t-butylmethylether (80:20, v/v) and vortexed for
5 min. From the clear lower organic layer the solvent was
removed through a constant nitrogen stream at room tempera-
ture (25 1C). The residue was dissolved with 100 ml of methanol,
sonicated, centrifuged for 5 min (15,000 rpm) and the super-
natant was ﬁnally transferred to autosampler vials (Macherey-
Nagel vial N9, 0.2 ml with integrated insert; Macherey-Nagel,
Düren, Germany).
2.7.3. Quantiﬁcation of valerenic acid by LC–MS/MS
The samples (10 ml) were analyzed by liquid chromatography/
mass spectrometry (LC–MS/MS) on an Ultimate 3000 RSLC-
series system (Thermo Fisher Scientiﬁc Austria, Vienna, Austria)
coupled to a triple quadrupol mass spectrometer (AB Sciex
Instruments API 4000) equipped with an orthogonal APCI source
operated in negative mode and displayed with Analyst
1.5 software.
LC separation was performed on an Acclaim RSLC 120C18
column (3 mm, 1502.1 mm I.D., Thermo Fisher Scientiﬁc Austria,
Vienna, Austria), preceded by an Acclaim 120C18 guard cartridge
(5 mm, 102 mm I.D., Thermo Fisher Scientiﬁc Austria, Vienna,
Austria), at a ﬂow rate of 0.500 ml/min and a column temperature
of 30 1C. The mobile phase consisted of a continuous linear
gradient, mixed from aqueous formic acid, pH 3.5 (mobile phase
A), and acetonitril (mobile phase B), to elute VA. The gradient
ranged from 50% B (0 min) to 80% at 8 min, kept constant at 80%
until 10 min, and ﬁnally decreased linearly to 50% again at 11 min.
Between sampling, the column was purged with 98% B (acetoni-
trile) for 4 min before equilibrating for 6 min resulting in a total
analysis time of 18 min. Within this setup valerenic acid eluted at
4.06 min., acetoxyvalerenic acid (IS) at 7.02 min. Selective and
sensitive detection and quantiﬁcation was carried out using MS/
MS fragmentation of VA resp. acetoxyvalerenic acid (ACVA) giving
a quasimolecular ion at m/z 233 [M–H] (VA) and m/z 291
[MH] (ACVA). MRM m/z 233/84 (VA) as well as m/z 291/249
(ACVA) were used for calibration curves to give a linear concen-
tration range from 0.1 ng/ml (LLOD, S/N¼4) to 500 ng/ml (correla-
tion coefﬁcient 0.9996). Extraction efﬁciencies (average 84%) were
determined by comparison of peak areas between quality control
(QC) and analysis samples. For validation, quality control (QC)
samples were prepared in the same way as the calibration
standards.
The triple quadrupol mass spectrometer operated with the
following parameters: APCI neg., NC-5, CUR 10, GS1 30, GS2 18,
TEM 400 1C, CAD 12, EP-11, DP-65, CXP-5, CEM 2100, DF 200. MRM
m/z 233/84 (VA): CE-29, dwell time 300 ms. MRM m/z 291/249
(ACVA): CE-24, dwell time 300 ms.
2.8. Statistical analysis
Statistical signiﬁcance of electrophysiological data was calculated
using a paired Student t-test; for in vivo experiments, one-way
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ANOVA (followed by posthoc Bonferroni analysis) was used. Statis-
tical analysis was done with Origin software (OriginLab Corpora-
tion; USA). P-values of o0.05 were accepted as statistically
signiﬁcant. All data are given as mean7S.E.M.
3. Results
3.1. IGABA modulation by VA-esters
Fig. 1 displays the structures of the studied VA-derivatives
(see Section 2 for synthesis). As expected, IGABA modulation by
VA-esters was less pronounced than by VA. This is shown in Fig. 2
illustrating modulation of IGABA through α1β3γ2S GABAA receptors
during co-application of GABA (EC3–7) and either VA, VA-ME,
VA-EE, VA-PE or VA-POM.
VA-ME and VA-EE induced signiﬁcantly stronger IGABA
enhancement than VA-PE and VA-POM (max. IGABA potentiation
(VA-ME 30 mM): 70713% (n¼5) and max. IGABA potentiation (VA-EE
30 mM): 52715% (n¼6) vs. max. IGABA potentiation (VA-PE 30 mM):
2776% (n¼5) and max. IGABA potentiation (VA-POM 30 mM): 2176%
(n¼6). Compared to VA the modulation of IGABA at 30 mM was
drastically reduced (from 6.2-fold (VA-ME) to 20.6-fold reduction
(VA-POM)). At 1 mM none of the studied ester derivatives induced
signiﬁcant IGABA enhancement (Fig. 2 A).
3.2. Anxiolytic action of VA-esters
For investigation of the time course of in vivo activity of the
different derivatives, effects on anxiety-related behavior were
tested 15, 30 and 60 min after i.p. application of either solvent
(¼control) or drug containing solutions at a dose of 3 mg/kg
bodyweight.
As illustrated in Fig. 3A, 15 min after injection, control mice
spent 29.772.7% of the total time (n¼33) in the open arms (OA)
of the EPM. An increase of time spent in the OAwas observed upon
application of VA-ME and VA-PE (VA-ME: 50.077.3%; n¼16,
Po0.01; VA-PE: 45.173.9%; n¼19; Po0.01) Animals treated with
VA-esters also covered signiﬁcantly longer distances on the OA
(Control: 327.8730.8 cm; n¼33 vs. VA-ME: 451.1753.4 cm;
n¼16, Po0.05 vs. VA-PE: 546.7737.1 cm; n¼19, Po0.01, see
Fig. 3D) suggesting anxiolytic activity. No signiﬁcant effects on
time spent in the OA, covered distance on the OA, OA and CA
entries were observed for VA-EE (Figs. 3 and 4A and D). Animals
treated with VA-POM covered a signiﬁcantly shorter distance on
the OA (Fig. 3D) and displayed fewer OA entries (Fig. 4A) compared
to control littermates, while no signiﬁcant effect on time spent on
the OA and CA entries was observed (Fig. 3A and Fig. 4D).
30 min after injection mice treated with VA, VA-ME, VA-PE
and VA-EE spent signiﬁcantly more time in the OA compared
to control mice (control: 32.873.1%; n¼19 vs. VA: 45.574.6%;
n¼14; Po0.05 vs. VA-ME: 51.975.5%; n¼13; Po0.01; VA-EE:
Fig. 2. IGABA modulation by VA-ester derivatives (A) Enhancement of IGABA through GABAA receptors composed of α1β3γ2S subunits by 1 mM (white bars), 10 mM (light grey
bars), 30 μM (dark grey bars) and 100 μM (black bars) of the indicated compounds. Each value represents the mean7S.E.M from at least 5 oocytes and Z2 oocyte batches.
(*) indicates signiﬁcantly different from IGABA enhancement by VA at the same concentration (Po0.05, Student's t-test) (B) Typical traces for the potentiation of chloride
currents through α1β3γ2S channels by VA-derivatives at a GABA EC3–7. Control currents (GABA, single bar) and corresponding currents elicited by co-application of GABA and
the indicated compound (double bar) are shown.
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51.375.4%; n¼15; Po0.01; VA-PE: 48.773.7%; n¼17; Po0.01;
see Fig. 3B). These increase in time spent in the OA was accom-
panied by longer distances covered on the OA compared to control
animals (Control: 370.4732.4 cm; n¼19 vs. VA: 521.2755.1 cm;
n¼14, Po0.05 vs. VA-ME: 655.9762.6 cm; n¼13, Po0.01; VA-
EE: 611.8773.7 cm; n¼15, Po0.01; VA-PE: 618.37100.0 cm;
n¼17, Po0.05; Fig. 3E). Mice treated with VA and VA-PE also
visited the OA more frequently, while no effect on OA visits upon
VA-ME and VA-EE application was observed (Fig. 4B). Interestingly,
signiﬁcantly increased ambulation on the OA (482.6744.9 cm;
n¼15, Po0.05; Fig. 3E) and a higher number of OA visits (Fig. 4B)
were also observed for mice treated with VA-POM compared to
control littermates. However, time spent on the OA did apparently
not differ signiﬁcantly from control (Fig. 3B). No differences in the
number of CA entries between control and compound treated mice
were observed 30 min after application (Fig. 4E).
As illustrated in Figs. 3 and 4C, 60 min after injection, the
exploratory drive (time spent in OA and OA entries) in mice
Fig. 3. Effects on explorative behavior of VA-esters in the elevated plus maze test are compared to saline-treated control (white bars) mice at a dose of 3 mg/kg bodyweight.
Bars display the time spent (in % of the total time) on the open arms ((A)–(C)) and the open arm distance ((D)–(F)) 15 (left column), 30 (mid column) and 60 (right column)
min after i.p. application of the indicated compounds. Each bar represents a mean7S.E.M from at least 8 different mice. (n) indicates statistically signiﬁcant differences with
Po0.05, (nn) with Po0.01 to control.
Fig. 4. Number of entries to the open (OA; (A)–(C)) and closed arms (CA; (D)–(F)) of the elevated plus maze 15 (left column), 30 (mid column) and 60 (right column) min
after i.p. application of the indicated compound are compared to control (white bars) at a dose of 3 mg/kg bodyweight. Each bar represents a mean7S.E.M from at least
8 different mice. (n) indicates statistically signiﬁcant differences with Po0.05, (nn) with Po0.01 to control.
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treated with VA was not signiﬁcantly different from control
animals, although mice covered a longer distance on the OA
(Control: 369.6740.3 cm; n¼15 vs. VA: 508.2752.5 cm; n¼17,
Po0.05; Fig. 3F). In contrast, application of VA-ME, VA-EE and
VA-PE induced increased ambulation of open arms also 60 min
after treatment (VA-ME: 56.776.3%; n¼14; Po0.01; VA-EE:
62.977.2%; n¼8; Po0.05; and VA-PE: 47.675.1%; n¼10;
Po0.05; Fig. 3C) accompanied by longer distances on the OA
(VA-ME: 601.0781 cm.2; n¼14, Po0.05 vs. VA-EE:
589.8776.1 cm; n¼8, Po0.05 vs. VA-PE: 532.7770.5 cm;
n¼10, Po0.05; Fig. 3F). Furthermore, while the number of OA
entries did not differ from control, the number of CA entries
signiﬁcantly dropped upon treatment with VA-ME and VA-EE
compared to control mice (Fig. 4C and F). Weaker, yet signiﬁcant
effects on time spent in the OA were also observed for mice
treated with VA-POM (44.477.0%; n¼12; Po0.05), while the
other parameters did signiﬁcantly not differ from control
(Figs. 3 and 4C and F).
No signiﬁcant changes in total distance were observed for any
drug at any time point, suggesting no sedative effects at this dose.
3.3. Anticonvulsant action of VA-esters
Loreclezole, a GABAA receptor modulator selective for β2/3
subunits, displays in vivo anticonvulsant activity (Greenﬁeld,
2013; Groves et al., 2006; Sanna et al., 1996; Wingrove et al.,
1994). It was therefore interesting to study if VA and the ester
derivatives would induce comparable effects.
Application of VA induced an increased threshold against
pentylenetetrazole (PTZ)-induced seizures 30 min after application
of VA (control: 39.572.8 mg/kg; n¼7 vs. VA: 49.071.8 mg/kg;
n¼4; Po0.05). No anticonvulsant effect was observed either at 15
or 60 min after VA application (see Fig. 5A). In contrast to
VA, VA-ME signiﬁcantly increased seizure threshold already
15 min after application (48.870.5 mg/kg; n¼4; Po0.01). The
anticonvulsant effect persisted 30 min after treatment
(50.070.5 mg/kg; n¼3; Po0.05), however, VA-ME did not induce
any signiﬁcant effects on seizure threshold 60 min after application.
In contrast to VA, VA-EE did not induce anticonvulsant effects
until 60 min after drug treatment (control: 39.572.8 mg/kg; n¼7
vs. 47.572.4 mg/kg; n¼3; Po0.05). Seizure threshold was further
signiﬁcantly increased 90 min after application (52.072.3 mg/kg;
n¼4; Po0.05) and remained at the same level even 120 min after
application (51.772.6 mg/kg; n¼4; Po0.05). 150 min after appli-
cation the seizure threshold of VA-EE-treated mice did not differ
from the control (see Fig. 5B).
As illustrated in Fig. 5C, VA-PE’s anticonvulsant activity was
comparable to VA: Seizure threshold was signiﬁcantly elevated
30 min after compound application (control: 39.572.8 mg/kg;
n¼7 vs. VA-PE: 54.771.3 mg/kg; n¼4; Po0.05). The seizure
threshold elevation at this time point was even more pronounced
than that of VA or the other derivatives (Po0.05). However, no
statistically signiﬁcant anticonvulsant effects could be detected at
a later time point.
No signiﬁcant changes in seizure threshold were observed upon
application of VA-POM until 60 min. At this time point VA-POM
signiﬁcantly increased seizure threshold (control: 39.572.8 mg/kg;
n¼7 vs. VA-POM: 48.472.1 mg/kg; n¼4; Po0.05). No anticonvul-
sant activity, however, was observed 90min after application (Fig. 5D).
As shown in Table 1 high concentrations of free VA could be
detected in plasma samples already after 15 min indicating rapid
hydrolysis of the VA-esters.
4. Discussion
Valerenic acid, from V. ofﬁcinalis, is an efﬁcient modulator of
GABAA receptors. VA binds with nanomolar afﬁnity, modulates
Fig. 5. Changes in seizure threshold upon PTZ-infusion are compared at a dose of 3 mg/kg bodyweight of VA (dotted line) and (A) VA-ME, (B) VA-EE, (C) VA-PE and
(D) VA-POM. Each data point represents the mean7S.E.M from at least 3 mice; (n) indicates statistically signiﬁcant differences with Po0.05; (nn) indicates statistically
signiﬁcant differences with Po0.01 to VA.
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IGABA at low micromolar concentrations and causes anxiolysis in
rodents with little sedation (Benke et al., 2009; Khom et al., 2010,
2007). VA speciﬁcally interacts with receptors containing β2 and
β3 subunits (Benke et al., 2009; Khom et al., 2007). A point
mutation in the β3 subunit (N265M) prevents anxiolytic activity
of VA in mice. It was therefore concluded that anxiolysis occurs via
neurons expressing β3 comprising GABAA receptors (Benke et al.,
2009). Subunit-selective ligands like VA would be expected to
exhibit a selective therapeutic proﬁle with fewer side effects and
may thus represent an interesting lead structure for the develop-
ment of novel GABAA receptor modulators (Atack, 2011a, 2011b,
2010; Möhler, 2012).
Little is known, however, if different VA-esters with higher
lipophilicity would have different anxiolytic and anticonvulsant
action. Neuhaus et al. (2008) hypothesized that VA does not
permeate the blood-brain barrier by passive diffusion through
the lipid bilayer but rather via a paracellular transport route.
Therefore, we have now performed a proof-of-concept study to
test if masking the carboxylic acid of VA by esteriﬁcation (Fig. 1)
would affect the in vivo activity of VA. Four VA-esters with
different lipophilicity (LogP: VA (5.1370.31)oVA-ME (5.647
0.28)oVA-EE (6.1770.28)oVA-PE (6.7070.28)oVA-POM
(6.9770.40), Fig. 1; calculated using ACD/ChemSketch freeware)
were designed and their anxiolytic and anticonvulsant activity
subsequently analyzed.
As expected, esteriﬁcation of VA signiﬁcantly reduced IGABA
modulation (Fig. 2), which was evident for all 4 tested derivatives.
None of the VA-esters increased IGABA at 1 mM, while signiﬁcant
stimulation was induced by VA (Fig. 2).
It is expected that the esters are transformed into the highly
active VA by esterases ubiquitously found in the blood, liver, brain
and other organs and tissues (Liederer and Borchardt, 2006). This
assumption is in line with the observed in vivo action of the
VA-esters (VA-ME, VA-EE and VA-PE, Figs. 3–5) and was directly
conﬁrmed by estimation of the plasma concentrations of VA
(Table 1).
In order to obtain information about potential differences in
the time courses of anxiolytic activity of esters, behavior was
analyzed 15, 30, 60 min after treatment. As shown in Figs. 3 and 4,
methylation and propylation of VA resulted in a faster onset of
anxiolysis, while VA-EE and VA-POM displayed no activity after
15 min. All esters were almost equally active after 30 min with the
exception of the VA-POM that did not cause signiﬁcant anxiolysis
(Fig. 3B). A longer lasting anxiolytic action of VA-ME and VA-EE is
evident from Fig. 3C where both compounds were at 60 min
signiﬁcantly more active than VA. These alterations may depend
on different factors including distinct distribution of the prodrug
into organs dependent on its lipophilicity. This may also include
alterations of binding to plasma proteins or fatty tissue. A second
important factor is the conversion of the non-active prodrug into
the active VA by esterases.
The anticonvulsant activity of VA and the ester derivatives was
observed for the ﬁrst time. Signiﬁcant differences in onset and
length of the anticonvulsant action of the VA-esters are evident
from Fig. 5. VA (dotted line in Fig. 5A–D) displayed little activity
after 15 min, reached maximal anticonvulsant activity after 30 min
that decayed until 90 min. A comparable transient time course of
action was observed for the propylester (VA-PE) displaying, how-
ever, signiﬁcantly stronger effects at 30 min. An exceptional result
was obtained with the ethylester of VA: remarkably, VA-EE
displayed no signiﬁcant anticonvulsant activity at early time
points (15 and 30 min, Fig. 5B). However, a long-lasting antic-
onvulsant action of this compound until 120 min is evident from
Fig. 5B. The anticonvulsant action of VA-POM was similarly
delayed but not so long lasting as VA-EE (compare Fig. 5B and
D). The late anticonvulsant effects of VA-EE (Fig. 5B) are in line
with its pronounced anxiolytic effect after 60 min (Fig. 3C). In
contrast, VA-ME displayed highest anxiolytic and anticonvulsant
activities at the earliest time-point (15 min). The most lipophilic
VA-POM displayed the least anxiolytic or anticonvulsant activity
compared to the most polar VA. This might relate to two possible
explanations: either the ethylester is stronger bond to proteins or
lipophilic surfaces, leading to a slower but longer distribution, or
the ethylester is less accessible for esterases, leading to an
increased stability of this potential prodrug. The ﬁrst reason
appears unlikely, because the lipophilicity of the ethylester is
comparable to those of the methyl- and propylesters, which both
display faster onset of effects. Of note is the fact, that the most
lipophilic ester (VA-POM) displayed comparatively little in vivo
activity, suggesting that this compound might be trapped in
lipophilic structures.
Hydrolysis of VA-esters in plasma was conﬁrmed employing an
LC–MS/MS assay as already described (Sampath et al., 2012).
Plasma levels after i.p. application of any of the VA-esters after
15 min were lower than after application of VA despite the
stronger in vivo activity (Figs. 3–5). Tissue binding and delayed
hydrolysis of VA-esters by esterases might contribute to the lower
plasma levels of VA.
However, in vivo VA-esters were similarly or even more
active than VA (VA-ME, VA-EE, VA-PE) (see Figs. 3–5) which may
indicate a rapid penetration of these potential prodrugs into brain.
Based on their lipophilicity it cannot be excluded that parent
VA-esters may reach signiﬁcant brain concentration. Although
esteriﬁcation of VA strongly reduces IGABA modulation in vitro
(Fig. 2) their potentially better penetration of the blood–brain
barrier may contribute to the overall anxiolytic and anticonvulsant
activity. The much slower onset and longer lasting anticonvulsant
activity of VA-EE and VA-POM may reﬂect a slower hydrolysis
in the brain (see Fig. 5B and D). Ongoing animal studies
shall therefore verify time- and dose-dependent penetration of
VA-esters into brain.
Taken together, several VA-esters display similar or stronger
in vivo activity than VA. The different time courses of anticonvulsant
activity (e.g. fast onset of the VA-ME and long lasting effects of the
VA-EE) may be beneﬁcial for potential therapeutic use of this
molecule. Future studies will show whether the increased lipophili-
city of the esters will affect the oral bioavailability of VA.
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Table 1
Plasma concentrations of free VA; 15, 30 and 60 min after application of VA and
VA-esters (3 mg/kg bodyweight) are indicated in ng/ml. Each data point represents
the mean7S.E.M of 4 animals per group.
Compound 15 min 30 min 60 min
VA 640.77131.8 105.2718.6 61.3721.8
VA-ME 164.2747.2 76.7719.7 24.274.3
VA-EE 117.4719.3 84.1711.3 20.274.1
VA-PE 274.5751.8 174.6752.3 43.776.7
VA-POM 166.579.1 80.4727.1 1171.5
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